Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

The FDA has endorsed plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific's experimental treatment for ...

The ultrasound catheter is being tested in the PreVail-PH2 study, an early feasibility trial enrolling PH patients with left ...

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...

Low-dose metformin, a medication for type 2 diabetes, delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of pulmonary arterial hypertension (PAH) in rats, a study ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Six out of 10 people with pulmonary arterial hypertension who were followed for 10 years in an extension study are still ...

Pulmonary hypertension (PH) is an incurable and life-threatening disease characterized by high blood pressure in the lung arteries. The severe medical condition is diagnosed when the blood vessels ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Pulmonary hypertension (PH) is an incurable and life-threatening disease that occurs when the pulmonary arteries, which are responsible for transporting the blood from the heart to the lungs, become ...